Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
